Table 5.
Associations Between Clinicopathologic Characteristics and OS in Breast Cancer Skeletal Metastases Patients
| Variables | Number of Patients | Number of Events | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Age (years) | ||||||
| <55 | 96 | 30 | 1 | / | ||
| ≥55 | 116 | 50 | 1.306(0.829–2.058) | 0.250 | / | / |
| Histological grade | ||||||
| I–II | 76 | 19 | 1 | 1 | ||
| III–IV | 136 | 61 | 1.847(1.103–3.093) | 0.020 | 1.314(0.731–2.365) | 0.362 |
| ER status | ||||||
| (-) | 92 | 44 | 1 | 1 | ||
| (+) | 120 | 36 | 0.614(0.395–0.955) | 0.031 | 0.599(0.382–0.939) | 0.025 |
| PR status | ||||||
| (-) | 146 | 59 | 1 | / | ||
| (+) | 66 | 21 | 0.768(0.466–1.264) | 0.298 | / | / |
| HER2 status | ||||||
| (-) | 146 | 59 | 1 | / | ||
| (+) | 66 | 21 | 0.993(0.634–1.555) | 0.975 | / | / |
| Ki-67 | ||||||
| <14% | 71 | 32 | 1 | / | ||
| ≥14% | 141 | 48 | 0.806(0.515–1.264) | 0.348 | / | / |
| The number of involved sites of visceral metastases | ||||||
| 0 | 106 | 39 | 1 | / | ||
| 1 | 20 | 12 | 1.489(0.779–2.845) | 0.229 | / | / |
| >1 | 86 | 29 | 0.631(0.384–1.038) | 0.070 | / | / |
| The number of involved sites of bone metastases | ||||||
| 1 | 101 | 30 | 1 | 1 | ||
| 2–3 | 90 | 37 | 1.427(0.881–2.311) | 0.148 | 1.475(0.852–2.554) | 0.165 |
| >3 | 21 | 13 | 2.553(1.331–4.900) | 0.005 | 1.925(0.946–3.918) | 0.071 |
| Type of surgery | ||||||
| Breast-conserving surgery | 86 | 30 | 1 | / | ||
| Radical mastectomy | 126 | 50 | 1.429(0.908–2.250) | 0.123 | / | / |
| Radiotherapy to the primary site | ||||||
| No | 71 | 23 | 1 | / | ||
| Yes | 141 | 57 | 1.118(0.689–1.815) | 0.651 | / | / |
| Endocrine therapy | ||||||
| No | 172 | 67 | 1 | / | ||
| Yes | 40 | 13 | 0.710(0.392–1.287) | 0.259 | / | / |
| Targeted therapy | ||||||
| No | 97 | 40 | 1 | / | ||
| Yes | 115 | 40 | 0.682(0.440–1.059) | 0.089 | / | / |
| Bisphosphonate treatment | ||||||
| No | 53 | 21 | 1 | / | ||
| Yes | 159 | 59 | 0.903(0.549–1.487) | 0.688 | / | / |
| Surgery to the affected bone | ||||||
| No | 165 | 63 | 1 | / | ||
| Yes | 47 | 17 | 1.031(0.603–1.763) | 0.912 | / | / |
| Radiotherapy to the affected bone | ||||||
| No | 139 | 62 | 1 | 1 | ||
| Yes | 73 | 18 | 0.495(0.293–0.837) | 0.009 | 0.452(0.261–0.783) | 0.005 |
| NLR | ||||||
| <2.48 | 90 | 21 | 1 | |||
| ≥2.48 | 122 | 59 | 2.732(1.658–4.503) | <0.0001 | 2.044(1.211–3.451) | 0.007 |
| LMR | ||||||
| <3.43 | 120 | 36 | 1 | 1 | ||
| ≥3.43 | 92 | 44 | 0.381(0.238–0.609) | <0.0001 | 0.532(0.324–0.872) | 0.012 |
| CAR | ||||||
| <0.34 | 168 | 56 | 1 | 1 | ||
| ≥0.34 | 44 | 24 | 1.730(1.071–2.793) | 0.025 | 1.340(0.817–2.198) | 0.246 |
Note: Bold text: P value < 0.05.
Abbreviations: OS, overall survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; T, tumor; N, lymph node involvement; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; CAR, C-reactive protein/albumin ratio.